Ways to prevent adenoid regrowth after surgery

Preventing recurrence after adenoidectomy involves surgical and medical approaches, as well as treatment of comorbidities that are risk factors for regrowth of adenoid tissue.

Surgical methods to minimize recurrence

The key factor in prevention is complete removal of the adenoid tissue during the primary operation. Residual tissue 1 month after surgery leads to recurrence in 63.6% of cases. ^[1]

• Endoscopic control at the end of the operation significantly reduces recurrence. In a prospective study (350 children), endoscopic inspection of the nasopharynx after curettage with coagulation of remnants reduced the recurrence rate from 6.6% to 1.18% (follow-up of 2 years or more) ^[2]
• Endoscopic microdebrider (shaver) adenoidectomy (EMA) provides the most complete removal of tissue under direct visual control. In a comparative study (833 children), recurrence was 0% with EMA versus 3.6% with curettage, and the rate of residual tissue with curettage reached 36.7% ^[3]
• Coblation adenoidectomy gives better control of adenoid tissue than curettage, with a possible reduction in revision rates, although this advantage has not yet been confirmed by large studies. A combined technique (curettage + coblation) also showed no recurrences during long-term follow-up ^[4][5]
• Simultaneous tonsillectomy reduces the risk of revision adenoidectomy: children who had adenoidectomy alone without tonsillectomy had a 3.7-fold higher risk of repeat surgery ^[6]

Medical prevention

Intranasal corticosteroids (INCS) are the best-studied method of medical prevention of recurrence. Although most of the evidence concerns pre-operative use, their mechanism of action (reducing inflammation and lymphoid proliferation) also supports their use after surgery:

• A meta-analysis of 30 studies confirmed that INCS significantly reduce adenoid size (SMD −1.33) and the need for adenoidectomy (RR 0.30) ^[7][8]
• According to the AAO-HNS consensus (2023), INCS may be used for persistent OSA after adenotonsillectomy, acting on residual adenoid tissue and inflammation of the upper airway mucosa ^[9]
• Recommended drugs: intranasal mometasone or budesonide, a 6–12 week course ^[10][11]

Montelukast is a leukotriene receptor antagonist that reduces lymphoid proliferation:

• The AAO-HNS consensus (2023) recognizes montelukast as effective for mild/moderate persistent OSA after adenotonsillectomy ^[9]
• The ATS clinical guideline (2024) gives a conditional recommendation to add montelukast to INCS for persistent OSA (very low certainty of evidence). In a small study, montelukast combined with budesonide reduced the AHI from 3.9 to 0.3/hour ^[11]
• The FDA boxed warning about serious neuropsychiatric side effects of montelukast must be taken into account; the drug is preferable in children without prior behavioral or mood disorders ^[9][11]

Treatment of comorbidities

Given the established risk factors for recurrence, targeted treatment of comorbid conditions is an important part of prevention: ^[12][13]

A large study (65,106 children) confirmed that children with allergic rhinitis have a statistically significantly higher risk of repeat adenoidectomy at all time points from 6 months after the primary operation. This underlines the importance of active treatment of allergic rhinitis as a strategy to prevent recurrence. ^[13]

Saline nasal irrigation

Regular nasal irrigation with normal or hypertonic saline is a simple and safe method that helps reduce inflammation of the nasopharyngeal mucosa. In the MIST+ study, intranasal saline led to resolution of obstructive sleep-disordered breathing symptoms in 41% of children, comparable to the effect of INCS. Although data on preventing recurrence after surgery are limited, nasal irrigation can be considered an additional measure. ^[18]

Practical recommendations for preventing recurrence

• Using endoscopic control or a microdebrider during the primary operation to remove the tissue as completely as possible ^[2][3]
• Prescribing INCS (mometasone/budesonide) for 6–12 weeks after surgery, especially if there are risk factors ^[9][11]
• Active treatment of allergic rhinitis and control of GERD ^[12][13][16]
• Considering simultaneous tonsillectomy when indicated ^[6]
• Regular follow-up with endoscopic examination of the nasopharynx during the first 2 years after surgery ^[2]